Tempest Therapeutics, Inc. filings document material-event disclosures for a clinical-stage biotechnology company developing CAR-T cell therapy and small-molecule product candidates. The company’s 8-K filings include Regulation FD presentations, press releases on TPST-2003 clinical data, annual financial results, business updates, and exhibits describing corporate presentations and pipeline activity.
The filing record also covers capital-structure and governance matters, including Nasdaq-listed common stock, Series A Junior Participating Preferred Purchase Rights, a limited-duration stockholder rights plan, equity incentive plan amendments, and listing-compliance notices. Material agreement disclosures include the completed acquisition of dual-targeting CAR-T assets and related common stock consideration.
Tempest Therapeutics, Inc. reported that Chief Financial Officer Nicholas Maestas received a grant of employee stock options covering 140,000 shares of common stock at an exercise price of $1.64 per share. These options expire on March 30, 2036 and are held as a direct ownership position.
According to the vesting terms, 25% of the total shares will vest on March 31, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on Maestas’s continued service. Following this grant, he holds 140,000 options in this award.
Tempest Therapeutics, Inc. received an updated ownership report from several Versant-managed funds on Schedule 13D/A Amendment No. 7. The amendment reflects dilution of their stakes after the company sold additional common shares.
Versant Venture Capital VI, L.P. now reports beneficial ownership of 16,149 shares, or 0.1% of Tempest’s common stock. Versant Vantage II, L.P. reports 162,972 shares, or 1.1%. Versant Venture Capital IV, L.P. reports 90,084 shares, or 0.6%, and Versant Side Fund IV, L.P. reports 567 shares. Versant Ventures IV, LLC reports 90,651 shares, or 0.6%. Percentages are based on 14,344,034 shares outstanding as of March 25, 2026, per Tempest’s Form 10-K.
Tempest Therapeutics, Inc. is registering the resale of up to 2,777,781 shares of its common stock by selling stockholders.
The registration covers shares issued in a March 20, 2026 private placement (including 462,964 issued shares, 925,927 Series A Warrant shares, 925,927 Series B Warrant shares and 462,963 Pre-Funded Warrant shares). The company will not receive proceeds from resale of these shares. Shares outstanding were 14,344,034 as of March 30, 2026.
Tempest Therapeutics, Inc. is registering for resale up to 8,268,495 shares of its common stock on behalf of selling stockholders who received the shares under an Asset Purchase Agreement.
The prospectus states the Shares were issued in connection with the acquisition of CAR-T and related assets from Erigen LLC and Factor Bioscience Inc.; the company will not receive proceeds from resales. The prospectus discloses 14,344,034 shares outstanding as of March 25, 2026 and cites a closing market price of $1.73 per share on March 27, 2026. The registration statement is a shelf Form S-3 registration enabling resale "from time to time" by the named selling stockholders and any permitted transferees.
Tempest Therapeutics, Inc. is a clinical-stage oncology company focused on dual‑targeting CAR‑T cell therapies and first‑in‑class small molecules for difficult cancers and immunology indications.
In February 2026, Tempest closed an all‑stock acquisition of several dual‑targeting CAR‑T programs from Erigen and Factor, issuing 8,268,495 common shares and obtaining global rights outside Greater China, India, Turkey and Russia. Lead CAR‑T asset TPST‑2003, an autologous CD19/BCMA therapy for relapsed or refractory multiple myeloma, has shown early but striking activity, including a 100% complete response rate (6/6) in the REDEEM‑1 Phase 1/2a trial and a 100% overall response rate (25/25) across REDEEM‑1 and an investigator‑initiated trial.
Amezalpat, a selective oral PPARα antagonist for first‑line unresectable or metastatic hepatocellular carcinoma, delivered a six‑month median overall survival improvement (21 vs. 15 months) and a hazard ratio of 0.65 in a randomized global Phase 1b/2 study, and has received FDA orphan drug and Fast Track designations as well as EMA orphan drug status. Tempest plans a pivotal Phase 3 trial via partners, while advancing TPST‑1495 into a National Cancer Institute‑funded Phase 2 study in familial adenomatous polyposis and progressing allogeneic and in vivo CAR‑T candidates. As of March 25, 2026, Tempest had 14,344,034 common shares outstanding and a non‑affiliate equity market value of about $30.1 million as of June 30, 2025.
Tempest Therapeutics reported full-year 2025 results and a broad clinical update. The company ended 2025 with $7.7 million in cash and cash equivalents, down from $30.3 million a year earlier, reflecting operating cash use partly offset by equity offerings.
Net loss for 2025 was $26.3 million, or $6.33 per share, compared with $41.8 million and $19.50 in 2024, as research and development expenses fell to $12.6 million from $28.5 million after reprioritizing efforts. General and administrative expenses were $14.0 million, slightly above $13.6 million in 2024 due to one-time separation costs.
Strategically, Tempest completed an all-stock acquisition of dual-targeting CAR‑T assets from Factor Bioscience, including lead program TPST‑2003, which showed a 100% complete response rate in six efficacy‑evaluable rrMM patients in the REDEEM‑1 Phase 1/2a trial with a favorable safety profile. The company also advanced amezalpat and TPST‑1495 with multiple orphan and Fast Track designations and outlined plans for a potential U.S. registrational study of TPST‑2003 and new Phase 2 trials in 2026.
Matthew Angel filed an amended ownership report showing a large stake in Tempest Therapeutics. He now beneficially owns 5,531,516 shares of common stock, representing 37.4% of Tempest Therapeutics’ outstanding shares, based on 14,344,334 shares outstanding immediately after a March 24, 2026 financing.
Angel’s position reflects shares received through Erigen LLC from an asset purchase that issued 8,268,495 Tempest shares to Erigen on November 19, 2025, later distributed to Erigen equityholders, as well as shares and warrants acquired indirectly through Factor Bioscience Inc. in a March 20, 2026 private placement. Related agreements include an asset purchase agreement, a lock-up on 50% of Erigen’s shares for 180 days after closing, a securities purchase agreement, registration rights for resale of shares and warrant shares, and common warrants issued to Factor.
Tempest Therapeutics director and CEO Matthew Angel reported an indirect open-market purchase of 231,482 shares of Common Stock at $2.16 per share. The shares are held by Factor Bioscience Inc., where he serves as chief executive officer and chairman, and he disclaims beneficial ownership except for his proportionate pecuniary interest.
Following this transaction, Factor Bioscience Inc. holds 231,482 shares indirectly attributed to Angel, while he also directly holds 4,837,070 shares of Tempest Therapeutics Common Stock. A footnote explains that the reported holdings reflect pro rata share distributions by Erigen LLC that changed only the form of his ownership.
Tempest Therapeutics, Inc. entered into a private placement with institutional and strategic investors, agreeing to sell 462,964 common shares and pre-funded warrants for up to 462,963 additional shares, each paired with Series A and Series B common stock warrants. The deal is priced at $2.16 per share-and-warrants and $2.159 per pre-funded-warrant-and-warrants, for expected gross proceeds of approximately $2.0 million, plus up to about $4.0 million more if the common warrants are exercised in cash. Tempest plans to use the net proceeds mainly for working capital and general corporate purposes, and will seek stockholder approval for warrant share issuance and register the resale of the issued and underlying shares.
Tempest Therapeutics reported promising interim data for TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma from the ongoing Phase 1/2a REDEEM-1 trial and a prior IIT.
As of January 31, 2026, 36 patients had received TPST-2003. All six efficacy-evaluable patients in REDEEM-1 achieved complete responses, and among 25 evaluable patients with measurable disease across both studies, the overall response rate was 100% (25/25). Patients in REDEEM-1 had a median of four prior lines of therapy, underscoring the heavily pretreated population. A favorable safety profile was observed across dose levels.
Based on these results, Tempest plans to accelerate development, submit a U.S. IND, and, subject to clearance, initiate a U.S. registrational study of TPST-2003 in 2026, while also exploring additional indications such as large B-cell lymphoma.